+357 96 030922
info@marketpublishers.com

Global TROP2 Antibody-Drug Conjugate Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/GA44E6734776EN.html
Date: September 2026
Pages: 90
Price: US$ 4,480.00 (Single User License)
ID: GA44E6734776EN

Abstracts

The global TROP2 Antibody-Drug Conjugate market size is expected to reach $ 4556 million by 2032, rising at a market growth of 13.3% CAGR during the forecast period (2026-2032).

TROP2 Antibody-Drug Conjugate refers to targeted anticancer therapeutics that combine a monoclonal antibody directed against trophoblast cell-surface antigen 2 (TROP2) with a cytotoxic payload through a designed chemical linker. After binding to TROP2-expressing tumor cells, the ADC is internalized or releases active payload within the tumor microenvironment, enabling targeted delivery of potent cytotoxic agents while seeking to improve the therapeutic index relative to conventional systemic chemotherapy. The current commercial product scope is centered on sacituzumab govitecan, datopotamab deruxtecan and sacituzumab tirumotecan, representing differentiated architectures based on SN-38, DXd and belotecan-derived topoisomerase I inhibitor payloads, respectively. Linker design ranges from hydrolyzable systems to tetrapeptide-based cleavable and other proprietary linker technologies, creating differences in payload release, bystander activity, stability and safety profiles. Commercial use currently spans TROP2 ADC monotherapy and combination regimens, with principal applications in triple-negative breast cancer, HR-positive/HER2-negative breast cancer and EGFR-mutated non-small cell lung cancer.

Key Findings

Commercial TROP2 ADC market centers on three approved core molecules

Breast cancer remains the principal commercial application for TROP2 ADCs

+357 96 030922
info@marketpublishers.com

EGFR-mutated NSCLC is an established commercial expansion pathway

Topoisomerase I inhibitor payloads dominate current commercial product architectures

Earlier-line and combination regimens are reshaping addressable treatment settings

Market Trends

The TROP2 Antibody-Drug Conjugate market is moving from a predominantly later-line rescue-treatment model toward broader positioning across treatment sequences. Recent regulatory progress illustrates this transition: datopotamab deruxtecan obtained U.S. approval for HR-positive/HER2-negative breast cancer in January 2025, EGFR-mutated NSCLC in June 2025 and selected unresectable or metastatic TNBC in May 2026, while Trodelvy expanded into first-line metastatic TNBC in the United States in June 2026. In China, sacituzumab tirumotecan has continued to broaden its approved breast cancer and EGFR-mutated NSCLC indications. These developments indicate that market competition is increasingly shifting from simply establishing TROP2 as a valid target toward optimizing ADC architecture, treatment-line positioning and combination strategies. Product development is also placing greater emphasis on linker stability, payload characteristics, bystander effect and tolerability, as these parameters influence whether TROP2 ADCs can penetrate earlier treatment lines and larger patient populations.

Market Dynamics

Drivers

The primary market driver is the continuing unmet treatment need in advanced breast cancer and EGFR-mutated NSCLC after resistance or progression following established systemic therapies. TROP2 provides a clinically validated cell-surface target for delivering highly potent topoisomerase I inhibitors, allowing ADCs to combine antibody-guided targeting with cytotoxic activity. Expansion of regulatory labels is progressively increasing the eligible patient population, particularly as products move from heavily pretreated patients toward earlier treatment lines. The commercial validation of multiple

+357 96 030922
info@marketpublishers.com

differentiated TROP2 ADC platforms also strengthens physician familiarity with the modality and supports investment in additional indication development, combination regimens and lifecycle expansion.

Restraints

Market expansion is constrained by the safety-management requirements inherent to highly potent ADCs and by the complexity of manufacturing antibody, linker and cytotoxic payload components as one consistently controlled pharmaceutical product. Different TROP2 ADCs exhibit distinct toxicity profiles: Trodelvy labeling highlights clinically important neutropenia and diarrhea, while datopotamab deruxtecan requires management of risks including interstitial lung disease or pneumonitis, ocular adverse reactions and stomatitis. These adverse-event profiles can influence patient selection, monitoring intensity, dose management and treatment sequencing. At the manufacturing level, stringent requirements for conjugation consistency, payload containment, analytical characterization and batch release also create higher technical barriers than conventional monoclonal antibody production.

Opportunities

The most attractive opportunities lie in increasing penetration within the three established application areas rather than relying solely on expansion into new tumor types. In TNBC and HR-positive/HER2-negative breast cancer, movement into earlier treatment lines could materially enlarge the addressable population, while combination regimens may extend the role of TROP2 ADCs beyond standalone therapy. In EGFR-mutated NSCLC, the emergence of approved TROP2 ADC options after targeted therapy and chemotherapy establishes a new commercial treatment category and creates opportunities for improved sequencing with existing targeted regimens. Continued optimization of linker-payload chemistry may further improve therapeutic index and help differentiate products within increasingly competitive breast and lung cancer treatment pathways.

Challenges

The principal long-term challenge is demonstrating sufficient clinical differentiation as several TROP2 ADCs compete for overlapping patient populations. Market success will increasingly depend on comparative efficacy, durability of response, safety, treatment-

+357 96 030922
info@marketpublishers.com

line positioning and compatibility with combination therapy rather than target novelty alone. Another challenge is treatment sequencing, particularly in breast cancer where oncologists have access to multiple targeted therapies and other ADC modalities. Biomarker strategy also remains important: TROP2 is broadly expressed, but optimal patient selection may depend on tumor biology, previous therapy and the specific characteristics of each ADC platform. Regulatory requirements for confirmatory studies, particularly where accelerated approval pathways are used, add further commercialization uncertainty.

Industry Chain Analysis

The TROP2 Antibody-Drug Conjugate industry chain integrates biologics manufacturing with highly potent small-molecule chemistry. Upstream inputs include anti-TROP2 monoclonal antibodies or antibody manufacturing materials, cytotoxic payload intermediates, linker compounds, conjugation reagents, cell-culture media, chromatography materials and specialized analytical technologies. The midstream stage involves antibody production, payload and linker synthesis, linker-payload preparation, controlled conjugation, purification, characterization, formulation and sterile fill-finish. Manufacturing quality depends not only on antibody purity but also on drug-to-antibody ratio, conjugation distribution, free payload levels, aggregation, linker stability and other critical quality attributes.

Value creation is therefore concentrated in integrated platform capability rather than in any single raw material. Companies able to coordinate antibody engineering, medicinal chemistry, conjugation technology, process development, analytical testing and commercial-scale manufacturing are better positioned to control product consistency and support indication expansion. Downstream commercialization is concentrated in oncology hospitals and specialist treatment networks, where medical affairs, reimbursement access, adverse-event management and physician education materially influence product adoption. The technical complexity of ADC production creates relatively high development and manufacturing barriers, while commercial value is increasingly determined by clinical differentiation and the breadth of approved treatment settings.

Segment Insights

By Type, the current commercial market is structured around sacituzumab govitecan,

+357 96 030922
info@marketpublishers.com

datopotamab deruxtecan and sacituzumab tirumotecan, each representing a distinct TROP2 ADC platform. By Class, the products are differentiated primarily by topoisomerase I inhibitor payload technology: SN-38, DXd and a belotecan-derived payload. Although all three architectures use the same broad cytotoxic mechanism class, differences in payload potency, membrane permeability, drug-to-antibody ratio and release behavior create materially different pharmacological profiles. Trodelvy uses a hydrolyzable linker linked to SN-38, datopotamab deruxtecan uses a tetrapeptide-based cleavable linker with a DXd payload, while sacituzumab tirumotecan uses a proprietary linker with a belotecan-derived topoisomerase I inhibitor payload.

By Sort, monotherapy currently provides the commercial foundation of the category, while combination therapy represents an increasingly important expansion direction. The distinction is strategically significant because a successful combination regimen can move a TROP2 ADC into earlier treatment lines and integrate it into established immunotherapy or targeted-treatment pathways. As the category matures, competitive differentiation is expected to shift increasingly toward the balance between efficacy, tolerability and ease of combination rather than target selection itself.

Downstream Market Opportunities

Downstream demand is concentrated in advanced and metastatic breast cancer and EGFR-mutated NSCLC treatment settings. TNBC offers substantial opportunity as TROP2 ADCs move from later-line treatment toward first-line use, while HR-positive/HER2-negative breast cancer provides a large post-endocrine-therapy population requiring additional systemic treatment options. In EGFR-mutated NSCLC, TROP2 ADCs address patients who progress after EGFR-targeted therapy and chemotherapy, establishing a clinically distinct downstream market. Future commercial upside within these applications will depend on earlier-line penetration, combination strategies, treatment duration, reimbursement accessibility and successful integration into oncology treatment algorithms. The most commercially attractive opportunity is therefore not simply adding more tumor types, but increasing the proportion of eligible patients within already validated breast and lung cancer pathways.

Regional Insights

North America and China are currently important commercialization and regulatory-development markets for TROP2 ADCs. The United States has experienced rapid label

+357 96 030922
info@marketpublishers.com

expansion across the established application spectrum: datopotamab deruxtecan has gained approvals in HR-positive/HER2-negative breast cancer, EGFR-mutated NSCLC and selected TNBC populations, while Trodelvy expanded into first-line metastatic TNBC in June 2026. This creates a relatively mature competitive environment in which treatment sequencing, clinical differentiation and combination use are becoming increasingly important.

China has developed a differentiated market structure around sacituzumab tirumotecan, which has progressively expanded from TNBC into EGFR-mutated NSCLC and HR-positive/HER2-negative breast cancer. By February 2026, the product had received approval for a fourth indication in China, demonstrating rapid lifecycle expansion within the defined market applications. Europe and Japan remain relevant commercial markets, but regional adoption is influenced by country-specific regulatory timing, reimbursement assessment and oncology-treatment pathways. These differences mean that global competition will not necessarily translate into identical product sequencing or commercial positioning across regions.

Competitive Landscape Analysis

The competitive landscape is defined by a small number of commercial TROP2 ADC platforms with increasingly overlapping indications. Gilead Sciences has established Trodelvy across TNBC and HR-positive/HER2-negative breast cancer and has expanded its U.S. positioning into first-line metastatic TNBC. Daiichi Sankyo and AstraZeneca jointly develop datopotamab deruxtecan, whose commercial footprint now spans HR-positive/HER2-negative breast cancer, EGFR-mutated NSCLC and selected TNBC populations in the United States. Kelun-Biotech has built sacituzumab tirumotecan into a commercial TROP2 ADC platform in China across the same major breast and lung cancer application areas. Competition is therefore evolving beyond first-mover advantage. Product architecture, efficacy-to-toxicity balance, treatment-line breadth, combination strategy, manufacturing capability, regulatory execution and market access are becoming more important determinants of competitive position. The market remains sufficiently concentrated for individual label expansions to alter competitive dynamics materially, particularly when they move a product into an earlier treatment line or a major additional application.

Report Scope

+357 96 030922
info@marketpublishers.com

This report studies the global TROP2 Antibody-Drug Conjugate demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for TROP2 Antibody-Drug Conjugate, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of TROP2 Antibody-Drug Conjugate that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global TROP2 Antibody-Drug Conjugate total market, 2021-2032, (USD Million)

Global TROP2 Antibody-Drug Conjugate total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: TROP2 Antibody-Drug Conjugate total market, key domestic companies, and share, (USD Million)

Global TROP2 Antibody-Drug Conjugate revenue by player, revenue and market share 2021-2026, (USD Million)

Global TROP2 Antibody-Drug Conjugate total market by Type, CAGR, 2021-2032, (USD Million)

Global TROP2 Antibody-Drug Conjugate total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global TROP2 Antibody-Drug Conjugate market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, Daiichi Sankyo, AstraZeneca, Sichuan Kelun-Biotech Biopharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

+357 96 030922
info@marketpublishers.com

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world TROP2 Antibody-Drug Conjugate market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global TROP2 Antibody-Drug Conjugate Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

Global TROP2 Antibody-Drug Conjugate Market, Segmentation by Type:

Intramuscular Injection

+357 96 030922
info@marketpublishers.com

Intravenous Injection

Global TROP2 Antibody-Drug Conjugate Market, Segmentation by Drugs Type:

Sacituzumab Govitecan

Datopotamab Deruxtecan

Sacituzumab Tirumotecan

Global TROP2 Antibody-Drug Conjugate Market, Segmentation by Treatment Mode:

ROP2 ADC Monotherapy

TROP2 ADC Combination Therapy

Global TROP2 Antibody-Drug Conjugate Market, Segmentation by Application:

Triple-Negative Breast Cancer

HR-Positive/HER2-Negative Breast Cancer

EGFR-Mutated Non-Small Cell Lung Cancer

Companies Profiled:

Gilead Sciences

Daiichi Sankyo

+357 96 030922
info@marketpublishers.com

AstraZeneca

Sichuan Kelun-Biotech Biopharmaceutical

Key Questions Answered

1. How big is the global TROP2 Antibody-Drug Conjugate market?
2. What is the demand of the global TROP2 Antibody-Drug Conjugate market?
3. What is the year over year growth of the global TROP2 Antibody-Drug Conjugate market?
4. What is the total value of the global TROP2 Antibody-Drug Conjugate market?
5. Who are the Major Players in the global TROP2 Antibody-Drug Conjugate market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 TROP2 Antibody-Drug Conjugate Introduction
1.2 World TROP2 Antibody-Drug Conjugate Market Size & Forecast (2021 & 2025 & 2032)
1.3 World TROP2 Antibody-Drug Conjugate Total Market by Region (by Headquarter Location)
  1.3.1 World TROP2 Antibody-Drug Conjugate Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032)
  1.3.3 China Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032)
  1.3.4 Europe Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032)
  1.3.5 Japan Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032)
  1.3.6 South Korea Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032)
  1.3.7 ASEAN Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032)
  1.3.8 India Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 TROP2 Antibody-Drug Conjugate Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032)
2.2 World TROP2 Antibody-Drug Conjugate Consumption Value by Region
  2.2.1 World TROP2 Antibody-Drug Conjugate Consumption Value by Region (2021-2026)
  2.2.2 World TROP2 Antibody-Drug Conjugate Consumption Value Forecast by Region (2027-2032)
2.3 United States TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032)
2.4 China TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032)
2.5 Europe TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032)
2.6 Japan TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032)

+357 96 030922
info@marketpublishers.com

2.7 South Korea TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032)
2.8 ASEAN TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032)
2.9 India TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032)

3 WORLD TROP2 ANTIBODY-DRUG CONJUGATE COMPANIES COMPETITIVE ANALYSIS

3.1 World TROP2 Antibody-Drug Conjugate Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
  3.2.1 Global TROP2 Antibody-Drug Conjugate Industry Rank of Major Players
  3.2.2 Global Concentration Ratios (CR4) for TROP2 Antibody-Drug Conjugate in 2025
  3.2.3 Global Concentration Ratios (CR8) for TROP2 Antibody-Drug Conjugate in 2025
3.3 TROP2 Antibody-Drug Conjugate Company Evaluation Quadrant
3.4 TROP2 Antibody-Drug Conjugate Market: Overall Company Footprint Analysis
  3.4.1 TROP2 Antibody-Drug Conjugate Market: Region Footprint
  3.4.2 TROP2 Antibody-Drug Conjugate Market: Company Product Type Footprint
  3.4.3 TROP2 Antibody-Drug Conjugate Market: Company Product Application Footprint
3.5 Competitive Environment
  3.5.1 Historical Structure of the Industry
  3.5.2 Barriers of Market Entry
  3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: TROP2 Antibody-Drug Conjugate Revenue Comparison (by Headquarter Location)
  4.1.1 United States VS China: TROP2 Antibody-Drug Conjugate Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
  4.1.2 United States VS China: TROP2 Antibody-Drug Conjugate Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: TROP2 Antibody-Drug Conjugate Consumption Value Comparison
  4.2.1 United States VS China: TROP2 Antibody-Drug Conjugate Consumption Value Comparison (2021 & 2025 & 2032)
  4.2.2 United States VS China: TROP2 Antibody-Drug Conjugate Consumption Value Market Share Comparison (2021 & 2025 & 2032)

+357 96 030922
info@marketpublishers.com

4.3 United States Based TROP2 Antibody-Drug Conjugate Companies and Market Share, 2021-2026
4.3.1 United States Based TROP2 Antibody-Drug Conjugate Companies, Headquarters (States, Country)
4.3.2 United States Based Companies TROP2 Antibody-Drug Conjugate Revenue, (2021-2026)
4.4 China Based Companies TROP2 Antibody-Drug Conjugate Revenue and Market Share, 2021-2026
4.4.1 China Based TROP2 Antibody-Drug Conjugate Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies TROP2 Antibody-Drug Conjugate Revenue, (2021-2026)
4.5 Rest of World Based TROP2 Antibody-Drug Conjugate Companies and Market Share, 2021-2026
4.5.1 Rest of World Based TROP2 Antibody-Drug Conjugate Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies TROP2 Antibody-Drug Conjugate Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World TROP2 Antibody-Drug Conjugate Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Intramuscular Injection
5.2.2 Intravenous Injection
5.3 Market Segment by Type
5.3.1 World TROP2 Antibody-Drug Conjugate Market Size by Type (2021-2026)
5.3.2 World TROP2 Antibody-Drug Conjugate Market Size by Type (2027-2032)
5.3.3 World TROP2 Antibody-Drug Conjugate Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY DRUGS TYPE

6.1 World TROP2 Antibody-Drug Conjugate Market Size Overview by Drugs Type: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Drugs Type
6.2.1 Sacituzumab Govitecan
6.2.2 Datopotamab Deruxtecan

+357 96 030922
info@marketpublishers.com

6.2.3 Sacituzumab Tirumotecan
6.3 Market Segment by Drugs Type
6.3.1 World TROP2 Antibody-Drug Conjugate Market Size by Drugs Type (2021-2026)
6.3.2 World TROP2 Antibody-Drug Conjugate Market Size by Drugs Type (2027-2032)
6.3.3 World TROP2 Antibody-Drug Conjugate Market Size Market Share by Drugs Type (2027-2032)

7 MARKET ANALYSIS BY TREATMENT MODE

7.1 World TROP2 Antibody-Drug Conjugate Market Size Overview by Treatment Mode: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Treatment Mode
7.2.1 ROP2 ADC Monotherapy
7.2.2 TROP2 ADC Combination Therapy
7.3 Market Segment by Treatment Mode
7.3.1 World TROP2 Antibody-Drug Conjugate Market Size by Treatment Mode (2021-2026)
7.3.2 World TROP2 Antibody-Drug Conjugate Market Size by Treatment Mode (2027-2032)
7.3.3 World TROP2 Antibody-Drug Conjugate Market Size Market Share by Treatment Mode (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World TROP2 Antibody-Drug Conjugate Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Triple-Negative Breast Cancer
8.2.2 HR-Positive/HER2-Negative Breast Cancer
8.2.3 EGFR-Mutated Non-Small Cell Lung Cancer
8.3 Market Segment by Application
8.3.1 World TROP2 Antibody-Drug Conjugate Market Size by Application (2021-2026)
8.3.2 World TROP2 Antibody-Drug Conjugate Market Size by Application (2027-2032)
8.3.3 World TROP2 Antibody-Drug Conjugate Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 Gilead Sciences

+357 96 030922
info@marketpublishers.com

9.1.1 Gilead Sciences Details
9.1.2 Gilead Sciences Major Business
9.1.3 Gilead Sciences TROP2 Antibody-Drug Conjugate Product and Services
9.1.4 Gilead Sciences TROP2 Antibody-Drug Conjugate Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Gilead Sciences Recent Developments/Updates
9.1.6 Gilead Sciences Competitive Strengths & Weaknesses
9.2 Daiichi Sankyo
9.2.1 Daiichi Sankyo Details
9.2.2 Daiichi Sankyo Major Business
9.2.3 Daiichi Sankyo TROP2 Antibody-Drug Conjugate Product and Services
9.2.4 Daiichi Sankyo TROP2 Antibody-Drug Conjugate Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Daiichi Sankyo Recent Developments/Updates
9.2.6 Daiichi Sankyo Competitive Strengths & Weaknesses
9.3 AstraZeneca
9.3.1 AstraZeneca Details
9.3.2 AstraZeneca Major Business
9.3.3 AstraZeneca TROP2 Antibody-Drug Conjugate Product and Services
9.3.4 AstraZeneca TROP2 Antibody-Drug Conjugate Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 AstraZeneca Recent Developments/Updates
9.3.6 AstraZeneca Competitive Strengths & Weaknesses
9.4 Sichuan Kelun-Biotech Biopharmaceutical
9.4.1 Sichuan Kelun-Biotech Biopharmaceutical Details
9.4.2 Sichuan Kelun-Biotech Biopharmaceutical Major Business
9.4.3 Sichuan Kelun-Biotech Biopharmaceutical TROP2 Antibody-Drug Conjugate Product and Services
9.4.4 Sichuan Kelun-Biotech Biopharmaceutical TROP2 Antibody-Drug Conjugate Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Sichuan Kelun-Biotech Biopharmaceutical Recent Developments/Updates
9.4.6 Sichuan Kelun-Biotech Biopharmaceutical Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 TROP2 Antibody-Drug Conjugate Industry Chain
10.2 TROP2 Antibody-Drug Conjugate Upstream Analysis
10.3 TROP2 Antibody-Drug Conjugate Midstream Analysis
10.4 TROP2 Antibody-Drug Conjugate Downstream Analysis

+357 96 030922
info@marketpublishers.com

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World TROP2 Antibody-Drug Conjugate Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World TROP2 Antibody-Drug Conjugate Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World TROP2 Antibody-Drug Conjugate Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World TROP2 Antibody-Drug Conjugate Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World TROP2 Antibody-Drug Conjugate Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World TROP2 Antibody-Drug Conjugate Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World TROP2 Antibody-Drug Conjugate Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World TROP2 Antibody-Drug Conjugate Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World TROP2 Antibody-Drug Conjugate Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key TROP2 Antibody-Drug Conjugate Players in 2025
Table 12. World TROP2 Antibody-Drug Conjugate Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global TROP2 Antibody-Drug Conjugate Company Evaluation Quadrant
Table 14. Head Office of Key TROP2 Antibody-Drug Conjugate Players
Table 15. TROP2 Antibody-Drug Conjugate Market: Company Product Type Footprint
Table 16. TROP2 Antibody-Drug Conjugate Market: Company Product Application Footprint
Table 17. TROP2 Antibody-Drug Conjugate Mergers & Acquisitions Activity
Table 18. United States VS China TROP2 Antibody-Drug Conjugate Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China TROP2 Antibody-Drug Conjugate Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based TROP2 Antibody-Drug Conjugate Companies, Headquarters (States, Country)

+357 96 030922
info@marketpublishers.com

Table 21. United States Based Companies TROP2 Antibody-Drug Conjugate Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies TROP2 Antibody-Drug Conjugate Revenue Market Share (2021-2026)
Table 23. China Based TROP2 Antibody-Drug Conjugate Companies, Headquarters (Province, Country)
Table 24. China Based Companies TROP2 Antibody-Drug Conjugate Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies TROP2 Antibody-Drug Conjugate Revenue Market Share (2021-2026)
Table 26. Rest of World Based TROP2 Antibody-Drug Conjugate Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies TROP2 Antibody-Drug Conjugate Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies TROP2 Antibody-Drug Conjugate Revenue Market Share (2021-2026)
Table 29. World TROP2 Antibody-Drug Conjugate Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World TROP2 Antibody-Drug Conjugate Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World TROP2 Antibody-Drug Conjugate Market Size by Type (2027-2032) & (USD Million)
Table 32. World TROP2 Antibody-Drug Conjugate Market Size by Drugs Type, (USD Million), 2021 & 2025 & 2032
Table 33. World TROP2 Antibody-Drug Conjugate Market Size Value by Drugs Type (2021-2026) & (USD Million)
Table 34. World TROP2 Antibody-Drug Conjugate Market Size by Drugs Type (2027-2032) & (USD Million)
Table 35. World TROP2 Antibody-Drug Conjugate Market Size by Treatment Mode, (USD Million), 2021 & 2025 & 2032
Table 36. World TROP2 Antibody-Drug Conjugate Market Size Value by Treatment Mode (2021-2026) & (USD Million)
Table 37. World TROP2 Antibody-Drug Conjugate Market Size by Treatment Mode (2027-2032) & (USD Million)
Table 38. World TROP2 Antibody-Drug Conjugate Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World TROP2 Antibody-Drug Conjugate Market Size by Application (2021-2026) & (USD Million)
Table 40. World TROP2 Antibody-Drug Conjugate Market Size by Application

+357 96 030922
info@marketpublishers.com

(2027-2032) & (USD Million)
Table 41. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 42. Gilead Sciences Major Business
Table 43. Gilead Sciences TROP2 Antibody-Drug Conjugate Product and Services
Table 44. Gilead Sciences TROP2 Antibody-Drug Conjugate Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Gilead Sciences Recent Developments/Updates
Table 46. Gilead Sciences Competitive Strengths & Weaknesses
Table 47. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 48. Daiichi Sankyo Major Business
Table 49. Daiichi Sankyo TROP2 Antibody-Drug Conjugate Product and Services
Table 50. Daiichi Sankyo TROP2 Antibody-Drug Conjugate Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Daiichi Sankyo Recent Developments/Updates
Table 52. Daiichi Sankyo Competitive Strengths & Weaknesses
Table 53. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 54. AstraZeneca Major Business
Table 55. AstraZeneca TROP2 Antibody-Drug Conjugate Product and Services
Table 56. AstraZeneca TROP2 Antibody-Drug Conjugate Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. AstraZeneca Recent Developments/Updates
Table 58. AstraZeneca Competitive Strengths & Weaknesses
Table 59. Sichuan Kelun-Biotech Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 60. Sichuan Kelun-Biotech Biopharmaceutical Major Business
Table 61. Sichuan Kelun-Biotech Biopharmaceutical TROP2 Antibody-Drug Conjugate Product and Services
Table 62. Sichuan Kelun-Biotech Biopharmaceutical TROP2 Antibody-Drug Conjugate Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Sichuan Kelun-Biotech Biopharmaceutical Recent Developments/Updates
Table 64. Sichuan Kelun-Biotech Biopharmaceutical Competitive Strengths & Weaknesses
Table 65. Global Key Players of TROP2 Antibody-Drug Conjugate Upstream (Raw Materials)
Table 66. Global TROP2 Antibody-Drug Conjugate Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. TROP2 Antibody-Drug Conjugate Picture
Figure 2. World TROP2 Antibody-Drug Conjugate Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World TROP2 Antibody-Drug Conjugate Total Revenue (2021-2032) & (USD Million)
Figure 4. World TROP2 Antibody-Drug Conjugate Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World TROP2 Antibody-Drug Conjugate Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company TROP2 Antibody-Drug Conjugate Revenue (2021-2032) & (USD Million)
Figure 13. TROP2 Antibody-Drug Conjugate Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 16. World TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Region (2021-2032)
Figure 17. United States TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 18. China TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)

+357 96 030922
info@marketpublishers.com

Figure 20. Japan TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 23. India TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of TROP2 Antibody-Drug Conjugate by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for TROP2 Antibody-Drug Conjugate Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for TROP2 Antibody-Drug Conjugate Markets in 2025
Figure 27. United States VS China: TROP2 Antibody-Drug Conjugate Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: TROP2 Antibody-Drug Conjugate Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World TROP2 Antibody-Drug Conjugate Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World TROP2 Antibody-Drug Conjugate Market Size Market Share by Type in 2025
Figure 31. Intramuscular Injection
Figure 32. Intravenous Injection
Figure 33. World TROP2 Antibody-Drug Conjugate Market Size Market Share by Type (2021-2032)
Figure 34. World TROP2 Antibody-Drug Conjugate Market Size by Drugs Type, (USD Million), 2021 & 2025 & 2032
Figure 35. World TROP2 Antibody-Drug Conjugate Market Size Market Share by Drugs Type in 2025
Figure 36. Sacituzumab Govitecan
Figure 37. Datopotamab Deruxtecan
Figure 38. Sacituzumab Tirumotecan
Figure 39. World TROP2 Antibody-Drug Conjugate Market Size Market Share by Drugs Type (2021-2032)
Figure 40. World TROP2 Antibody-Drug Conjugate Market Size by Treatment Mode, (USD Million), 2021 & 2025 & 2032
Figure 41. World TROP2 Antibody-Drug Conjugate Market Size Market Share by Treatment Mode in 2025

+357 96 030922
info@marketpublishers.com

Figure 42. ROP2 ADC Monotherapy
Figure 43. TROP2 ADC Combination Therapy
Figure 44. World TROP2 Antibody-Drug Conjugate Market Size Market Share by Treatment Mode (2021-2032)
Figure 45. World TROP2 Antibody-Drug Conjugate Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 46. World TROP2 Antibody-Drug Conjugate Market Size Market Share by Application in 2025
Figure 47. Triple-Negative Breast Cancer
Figure 48. HR-Positive/HER2-Negative Breast Cancer
Figure 49. EGFR-Mutated Non-Small Cell Lung Cancer
Figure 50. World TROP2 Antibody-Drug Conjugate Market Size Market Share by Application (2021-2032)
Figure 51. TROP2 Antibody-Drug Conjugate Industrial Chain
Figure 52. Methodology
Figure 53. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global TROP2 Antibody-Drug Conjugate Supply, Demand and Key Producers, 2026-2032
Product link: https://marketpublishers.com/r/GA44E6734776EN.html
Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GA44E6734776EN.html